Exabis Library
Welcome to the e-CCO Library!
P663: Primary prevention of post-operative recurrence of Crohn’s disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P663: Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P664: Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P664: Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P664: Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P664: Bidirectional association between inflammatory bowel disease and psoriasis in a pediatric population: A nationwide insurance claim data analysis in South Korea.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P664: The transitioning healthcare economy of IBD: changes in resource allocation over time
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P665: 1-Year clinical and endoscopic follow-up of vedolizumab therapy in refractory PIBD patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P665: Cardiovascular risk profile in chronic auto-inflammatory diseases: a cross-sectional single center study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P665: Higher BMI but not systemic immune suppression increases the risk of short-term postoperative complications in Crohn’s disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P665: Social Media Listening to better Understand the Lived Experience of Individuals With Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P665: Towards FAIR longitudinal IBD registries: preliminary results of an iterative design process of a reusable and interoperable IBD database model
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P665: Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P666 Neutropenia in inflammatory bowel disease patients on TNF inhibitors: A single-centre, retrospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P666: Effect of anastomotic configuration on Crohn's Disease recurrence after primary ileocolic resection. A comparative monocentric study of end-to-end versus side-to-side anastomosis.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P666: Frequency and outcome of SARS-CoV2 infection in patients with inflammatory bowel disease on different biological therapy
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM